학술논문

UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
Document Type
Journal
Source
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER; DEC 2022, 32 pA235-pA235, 1p. Supplement: 3
Subject
Language
English
ISSN
15251438